Background {#Sec1}
==========

Long-term graft survival is the key objective when determining the immunosuppressive regimen after kidney transplantation. The graft, however, is subject to multiple insults which can ultimately lead to irreversible nephron loss and progressive dysfunction, but this typically occurs relatively late such that graft function is a poor marker for the severity of histological changes. These include early tubulointerstitial damage from ischemia-reperfusion injury, acute and subclinical rejection, calcineurin inhibitor (CNI)-related nephrotoxicity, and viral infections \[[@CR1]\]. Up to 1 year post-transplant, subclinical rejection is found in 30--50% of stable grafts in patients treatment with cyclosporine (CsA) \[[@CR2]\], and in up to 15% of patients receiving tacrolimus \[[@CR3]--[@CR6]\], and is associated with subsequent tubulointerstitial damage \[[@CR7], [@CR8]\]. Subsequently, chronic microvascular and glomerular damage caused by interstitial fibrosis/tubular atrophy (IF/TA) becomes more common, affecting 50% of grafts by 2 years despite normal graft function \[[@CR7], [@CR8]\]. IF/TA is associated with reduced survival, particularly in the presence of inflammation \[[@CR9]\].

Minimizing exposure to CNI therapy is a well-established strategy to limit pathophysiological damage to the graft \[[@CR1]\]. Use of mammalian target of rapamycin (mTOR) inhibitors to facilitate pre-emptive CNI withdrawal after the initial post-transplant phase achieves a significant improvement in short- and long-term renal function versus a conventional CNI-based regimen if the conversion takes place by month 6 \[[@CR10]--[@CR13]\]. In two randomized trials, however, there was a significant \[[@CR10]\] or numerical \[[@CR13]\] increase in the rate of mild biopsy-proven acute cellular rejection (BPAR). The improved renal function during follow-up to as much as 5 years post-transplant is highly encouraging. High donor-specific antibody (DSA) values in a cohort of patients switched from CNI to everolimus have been reported in one single-center analysis \[[@CR14]\], potentially increasing the risk for acute humoral rejection. Histological data from patients randomized to a CNI-free immunosuppressive regimen versus CNI-based long-term therapy would provide further insights into whether humoral mechanisms are relevant for pathological injury in these grafts.

Five-year follow-up data have recently been reported from the ZEUS study, in which kidney transplant patients were randomized at month 4.5 to switch to the mTOR inhibitor everolimus or remain on CsA-based immunosuppression \[[@CR11]\]. The results showed significantly improved renal function in the everolimus-treated cohort at 5 years versus controls. BPAR occurred in 13.6 and 7.5% of patients in the everolimus and CsA cohorts, respectively (*p* = 0.095), with the difference in BPAR rates largely accounted for by grade I rejection \[[@CR11]\]. In the ZEUS trial, graft biopsies were requested at baseline, month 12 post-transplant, and as clinically mandated. We report here a detailed analysis of the full pathology findings from the study biopsies, including the presence of CNI-related toxicity, antibody-mediated rejection (AMR) and chronic/sclerosing allograft nephropathy.

Methods {#Sec2}
=======

Study design and patient population {#Sec3}
-----------------------------------

ZEUS was a 12-month multicenter, open-label, parallel-group trial in which kidney transplant recipients were randomized at 4.5 months post-transplant to convert to everolimus or remain on CsA therapy (NCT00154310). After completion of the 12-month study visit, patients were followed up at annual observational visits during an extension phase of the study until 5 years post-transplant. The study was undertaken at 17 transplant centers in Germany and Switzerland during June 2005 to September 2007, with the final five-year visit in September 2012. The study was conducted in compliance with Good Clinical Practice and the Declaration of Helsinki.

The study population comprised recipients of a kidney transplant aged 18--65 years. Key exclusion criteria at the time of transplantation were more than one previous renal transplantation, loss of previous graft due to immunological reasons in the first year post-transplant, multiple organ transplantation (e.g. kidney and pancreas), receipt of an organ donated after cardiac death, donor age \< 5 years or \> 65 years, historical or current peak panel reactive antibodies (PRA) \> 25%, platelets \< 75,000/mm^3^ with an absolute neutrophil count of \< 1500/mm^3^ or leucocytes \< 2500/mm^3^, hemoglobin \< 6 g/dl, or severe liver disease. Key inclusion criteria at 4.5 months post-transplant (the point of randomization) were treatment with CsA, enteric-coated mycophenolate sodium (EC-MPS, minimum dose of 720 mg/day) and corticosteroids, and serum creatinine ≤265 μmol/l. Key exclusion criteria at month 4.5 post-transplant were graft loss, previous rejection that was severe (Banff grade ≥ II), recurrent or steroid-resistant, dialysis dependency or proteinuria \> 1 g/day.

Immunosuppression {#Sec4}
-----------------

All patients received basiliximab induction therapy (Simulect®, Novartis Pharma AG, Basel, Switzerland). Until month 4.5, the immunosuppression regimen comprised CsA (Sandimmun® Optoral/Neoral®, Novartis Pharma AG) dosed according to pre-specified target ranges for trough concentration and concentration at 2 hours post-dose \[[@CR10]\], 1440 mg/day EC-MPS (Myfortic®, Novartis Pharma AG) and corticosteroids according to local practice.

At 4.5 months post-transplant, patients were stratified according to living or deceased donor and randomized using an automated, validated system. For patients randomized to the everolimus group, everolimus was initiated and CsA was withdrawn in a stepwise manner over a maximum of 4 weeks. The everolimus target C~0~ concentration was 6--10 ng/ml following CsA discontinuation. For patients randomized to continue CsA therapy, CsA dosing was adjusted according to tapered target ranges to month 12. After the month 12 study visit, the assigned immunosuppressive regimen was to be maintained but changes were permitted at any time based on each patient's clinical needs at the discretion of the investigator.

Graft biopsies {#Sec5}
--------------

Protocol biopsies were requested at time of transplant, the point of randomization (month 4.5) and at month 12. The study protocol also stipulated that graft core biopsies were to be performed in the event of a suspected rejection episode prior to (or at the latest within 24 h after) the initiation of anti-rejection therapy. If there was an inadequate response to a full course of steroids and initiation of antilymphocyte therapy was delayed for more than 10 days after the diagnosis of BPAR, a repeat biopsy was to be performed to confirm ongoing rejection. Biopsies were read and interpreted by a local pathologist, the results of which were used without histological re-evaluation for the current analysis. Data were captured in response to the following questions: Is there any histological evidence of acute/active rejection (with Banff grading)?; Is there any histological evidence of chronic/sclerosing allograft nephropathy (with Banff grading)?; Is there any evidence of AMR (severity graded as acute tubular necrosis \[ATN\]-like/minimal inflammation, capillary marginal and/or thrombosis, arterial v3 \[transmural inflammation/fibrinoid change\])?; Is C4d staining positive?; Presence of other lesions/abnormal findings (borderline lesions, ATN, acute allograft glomerulopathy, calcineurin toxicity lesions, donor lesions, chronic allograft glomerulopathy, other)? Follow-up biopsies are reported for all patients up to 5 years post-transplant.

Data analysis {#Sec6}
-------------

Data were analyzed from biopsies performed at the time of randomization or thereafter in the core or extension phases of the study. Biopsies undertaken in response to a clinical event, or as follow-up to a clinical event, were categorized as 'investigator-initiated' and were analyzed separately from protocol-specified biopsies performed at (i) randomization or (ii) month 12 or at the point of early study discontinuation. Pathological findings according to Banff 97 criteria \[[@CR15]\] and information on C4d staining are presented. The presence of CNI toxicity was defined according to local histopathology criteria. Histological changes characteristic of AMR are itemized. The final clinical diagnoses for all cases in which rejection was suspected and an investigator-initiated biopsy was undertaken are presented.

Data on rejection episodes were recorded during the 12-month study and at each annual follow-up visit up to 5 years post-transplant. The final clinical diagnoses of rejection events were captured up to 5 years post-transplant according to the following categories on the case report form: normal; infection; acute cellular rejection diagnosed by biopsy; acute and chronic rejection; recurrence of original disease; infarction/thrombosis; technical problem; post-transplant lymphoproliferative disorder; urinary obstruction; delayed graft function; acute tubular necrosis; urological problem; calcineurin inhibitor induced toxicity; chronic allograft nephropathy; borderline lesions; other.

The incidence of biopsy findings is presented per treatment group using two different denominators: (i) the number of patients with ≥1 biopsy (ii) the number of patients in the intent-to-treat (ITT) population. Between-group differences were compared using the T-test (two-sided), Fisher's test (two-sided) or Chi square test where appropriate.

Results {#Sec7}
=======

Patient population and study treatment {#Sec8}
--------------------------------------

The ITT population included 300 patients (everolimus 154, CsA 146). The 12-month core study was completed by 269 patients (138 everolimus, 131 CsA) and the five-year visit was attended by 232 patients (123 everolimus, 109 CsA) (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). The characteristics of recipients and donors were similar between treatment groups other than body mass index, which was higher in the everolimus group (Additional file [1](#MOESM1){ref-type="media"}: Table S1). By year 5 post-transplant, 45.2% of patients randomized to everolimus remained on everolimus in a CNI-free regimen. In the CsA group, 58.6% of patients were still receiving CsA and a further 11 patients (7.6%) had switched to tacrolimus so remained on CNI therapy (Additional file [1](#MOESM1){ref-type="media"}: Table S2). For the patients in whom data were available regarding used of steroid therapy, 79/123 patients in the everolimus group (64.2%) and 70/109 patients in the CsA group (64.2%) were receiving steroids at 5 years post-transplant.

Biopsy samples {#Sec9}
--------------

Protocol biopsies were performed in 40 patients (13.3% of patients; 22 everolimus, 18 CsA) at randomization and in 34 patients (11.3% of patients; 17 everolimus, 17 CsA) at month 12. Prior to randomization at month 4.5, investigator-initiated biopsies were performed in 125 patients (41.7%), at a mean of 0.9 months post-transplant (Table [1](#Tab1){ref-type="table"}). In total, 178 investigator-initiated biopsies were performed after randomization, in 53 everolimus-treated patients (34.4%) and 53 CsA-treated patients (36.3%), of which 67 (67/178, 37.6%) were obtained by year 1 and 111 (111/178, 62.4%) were obtained during years 2--5 (Table [1](#Tab1){ref-type="table"}). The mean (SD) number of investigator-initiated biopsies per patient between randomization and year 5 was 2.6 (1.7) in the everolimus group compared to 2.2 (1.4) in the CsA group, at a mean of 20.2 (16.6) and 19.5 (15.8) months post-transplantation, respectively.Table 1Graft biopsies to year 5 post-transplantEverolimus\
(*n* = 154)CsA\
(*n* = 146)Number of patients with protocol-specified biopsies, n (%) Randomization n (%)22 (14.3)18 (12.3) Month 12, n (%)17 (11.0)17 (11.6)Number of patients with investigator-initiated biopsies, n (%) Before randomization61 (39.6)64 (43.8) After randomization  Core phase (to year 1)27 (17.5)26 (17.8)  Extension phase (years 2--5)39 (25.3)34 (23.3)  Total53 (34.4)53 (36.3)Total number of investigator-initiated biopsies, n Before randomization111115 After randomization  Core phase3334  Extension phase (years 2--5)6249  Total9583Mean (SD) number of investigator-initiated biopsies per patient, n Before randomization1.8 (1.0)1.8 (1.1) After randomization1.8 (1.2)1.6 (1.0)Time from transplant to first investigator-initiated biopsy, months Before randomization  Mean (SD)0.9 (0.9)0.9 (0.9)  Median (range)0.4 (0.2--3.7)0.5 (0.2--4.2) After randomization  Mean (SD)19.5 (15.8)20.2 (16.6)  Median (range)10.5 (4.3--59.5)13.3 (30.5--59.6)*CsA* cyclosporine, *SD* standard deviation

An additional 54 biopsy samples (34 everolimus, 20 CsA) in 26 patients (15 everolimus, 11 CsA) were provided but were inadequately categorized regarding reason for biopsy (i.e. protocol-mandated or investigator-initiated) and were excluded from analyses. Results from these samples are shown in Additional file [1](#MOESM1){ref-type="media"}: Table S3.

Pathology findings {#Sec10}
------------------

### Protocol biopsies {#Sec11}

Protocol biopsy results at randomization and at month 12 revealed few cases of clinically undetected mild BPAR or other lesions in either treatment group, but the number of such biopsies was low (Table [2](#Tab2){ref-type="table"}).Table 2Pathology assessment of biopsies according to Banff criteriaNo. events% based on number of patients with ≥1 biopsy% based on number of ITT patientsProtocol-specified biopsies, *n* (%)EverolimusCsAEverolimusCsA*P* value^a^*Biopsy at randomization2218n = 22n = 18----* BPAR grade 1A104.501.000-- Borderline lesions4318.216.71.000 Other114.55.61.000*Month 121717n = 17n = 17--* BPAR, any3117.65.90.601--  Grade 1A01  Grade 1B10  Grade 2A20 Chronic/sclerosing allograft nephropathy  Grade 1115.95.91.000 CNI toxicity lesions105.901.000 Borderline lesions3117.65.90.601Investigator-initiated biopsy, *n* (%)^b^EverolimusCsAEverolimus *N* = 61CsA *N* = 64*P* value^a^Everolimus *N* = 154CsA *N* = 146*P* value^a^*Before randomization6164n = 61n = 64--39.643.8--* BPAR, any111718.026.60.2887.111.60.234  Grade 1A97  Grade 1B02  Grade 2A10  Grade 2B02  Grade 300  Grade missing17 Antibody-mediated rejection223.33.11.0001.31.41.000 Chronic/sclerosing allograft nephropathy223.33.11.0001.31.41.000  Grade 111  Grade 211  Grade 300 CNI toxicity lesions172027.931.30.70011.013.70.489 Borderline lesions91514.823.40.2605.810.30.202 Acute tubular necrosis152124.632.80.3009.714.40.286 Chronic allograft glomerulopathy0101.61.00000.70.487 Donor lesions466.69.40.7442.64.10.533 Other162126.232.80.44010.414.40.380*After randomization5353n = 53n = 53--34.436.3--* BPAR, any191135.820.80.13112.37.50.182  Grade 1A108  Grade 1B61  Grade 2A62  Grade 2B00  Grade 312  Grade missing10 Antibody-mediated rejection141.97.50.3630.62.70.204 Chronic/sclerosing allograft nephropathy111220.822.61.0007.18.20.829  Grade 177  Grade 224  Grade 323 CNI toxicity lesions71513.228.30.0924.510.30.076 Borderline lesions141126.420.81.0009.17.50.680 Acute tubular necrosis213.81.91.0001.30.71.000 Chronic allograft glomerulopathy7413.27.50.5264.52.70.543 Donor lesions0203.80.49501.40.236 Other271450.926.4*0.016*17.59.60.063^a^Fisher's exact test (two-sided)^b^More than one biopsy was performed in some patients, so more than one grade per patient could be specified*BPAR* biopsy-proven acute cellular rejection, *CNI* calcineurin inhibitor, *CsA* cyclosporine, *ITT* intent-to-treat

### Investigator-initiated biopsies prior to randomization {#Sec12}

In the 125 patients who underwent biopsy prior to randomization, BPAR was present in 28 cases (22.4%), the majority of which were grade 1A (Table [2](#Tab2){ref-type="table"}). CNI-related lesions (*n* = 37) and acute tubular necrosis (*n* = 36) were more frequently observed than BPAR. AMR was rare (4/125, 3.2%).

### Investigator-initiated biopsies after randomization {#Sec13}

Among patients in whom post-randomization investigator-initiated biopsies were performed between randomization and year 5, BPAR was detected in 19 everolimus-treated patients (19/154, 12.3%; 10 episodes of grade 1A, 6 grade 1B, 6 grade 2A, 1 grade 3 \[1 missing\]) and 11 CsA-treated patients (11/146, 7.5%; 8 episodes of grade 1A, 1 grade 1B, 2 grade 2A, 2 grade 3) (*p* = 0.182) (Table [2](#Tab2){ref-type="table"}). The incidence from randomization to year 1 was 8.4% (13/154) versus 3.4% (5/146) in everolimus and CsA groups, respectively (*p* = 0.088), and 5.8% (9/154) versus 4.8% (7/146) during the extension phase (years 2--5) (*p* = 0.799). The severity of BPAR between randomization and year 5 was comparable between groups, with 22/24 episodes of BPAR in the everolimus group and 18/20 episodes in the CsA group graded mild (grade ≤ 2A).

The proportion of patients exhibiting chronic/sclerosing allograft nephropathy on investigator-initiated biopsies after randomization was 7.1% in the everolimus group and 8.2% in the CsA group (*p* = 0.829), and was graded mild (Banff grade ≤ 2A) in the majority of cases (Table [2](#Tab2){ref-type="table"}). Borderline lesions occurred with similar frequency in each group (*p* = 0.680). Pathologists reported CNI toxicity lesions in 7/154 (4.5%) and 15/146 (10.3%) of patients undergoing investigator-initiated biopsies in the everolimus and CsA groups, respectively (*p* = 0.076).

Post-randomization, AMR was detected in one everolimus-treated patient (0.6%) which was categorized as ATN-like and was C4d positive. Four CsA-treated patients developed AMR (2.7%): two showed ATN-like changes (both C4d positive), one had arterial-v3 changes (C4d positive) and one showed capillary-marginal change/thrombosis (C4d negative). C4d staining was detected in 17 everolimus-treated patients (11.0%) and 10 CsA-treated patients (6.8%), including one of the three patients in the everolimus group who developed AMR and three of the six CsA-treated patients with AMR.

When pathology diagnoses in investigator-initiated biopsy samples after randomization were compared as a proportion of patients undergoing biopsy, there was a higher rate of 'other' lesions in the everolimus cohort (50.9% versus 26.4%, *p* = 0.016) and a non-significant trend (*p* = 0.092) to a higher rate of CNI-related toxicity lesions in the CsA arm.

Clinical diagnoses following biopsy {#Sec14}
-----------------------------------

The final clinical diagnosis among patients with one or more investigator-initiated biopsy after randomization performed in response to suspected rejection (everolimus 52, CsA 50) is summarized in Table [3](#Tab3){ref-type="table"}.Table 3Final clinical diagnosis following a post-randomization investigator-initiated biopsy in response to suspected rejection^a^No. events% based on number of patients with ≥1 suspected rejection% based on number of ITT patientsEverolimusCsAEverolimus *N* = 52CsA *N* = 50*P* value^b^Everolimus *N* = 154CsA *N* = 146*P* value^b^Acute cellular rejection^c^172632.752.00.07111.017.80.102Acute & chronic rejection121.94.00.6140.61.40.614Borderline lesions171732.734.01.00011.011.61.000CNI-induced toxicity141426.928.01.0009.19.61.000Acute tubular necrosis467.712.00.5212.64.10.533Chronic allograft nephropathy9917.318.01.0005.86.21.000Infection0306.00.11402.10.114Normal131025.020.00.6388.46.80.668Other232044.240.00.69214.913.70.869^a^More than one clinical diagnosis was possible^b^Fisher\'s exact test (two-sided)^c^Includes diagnosis made in advance of biopsy results (everolimus 2, CsA 1)*CNI* calcineurin inhibitor, *CsA* cyclosporine

Discussion {#Sec15}
==========

Clinically-indicated renal biopsies from the randomized ZEUS study up to year 5 post-transplant showed a trend to more frequent mild acute cellular rejection, and approximately half the incidence of CNI-toxicity lesions, under an everolimus-based regimen with early CNI elimination versus standard CsA therapy. The between-group differences were not statistically significant, however, in the relatively small cohort of patients undergoing clinically-indicated biopsy after randomization. The severity of acute cellular rejection and rates of AMR and chronic allograft nephropathy were similar between groups following randomization. Consistent with this, the proportion of patients in whom a post-randomization biopsy was requested was also comparable with everolimus- or CsA-based treatment.

The surveillance biopsies which were requested in the study protocol at randomization and month 12 were performed in only a low proportion of patients, severely limiting interpretation. There was a numerically higher number of BPAR and borderline lesions in the everolimus group, but these were each observed in only three patients versus one patient in the CsA group, so conclusions cannot be drawn.

AMR was rare in both treatment arms after randomization (everolimus 0.6%, CsA 2.7%). The diagnosis was made based only on histological changes with or without C4d staining \[[@CR15]\], since, at that time, DSAs were not measured in most centers during the study. A subsequent protocol amendment specified that data on DSA levels should be collected at the five-year study visit, but this was provided for only 28 patients in the everolimus group and 25 patients in the CsA group, and, in this subset of patients, no difference was found between treatment groups \[[@CR11]\]. In the recent CENTRAL study, which randomized kidney transplant patients at week 7 to switch to everolimus or remain on CsA, DSA was detected in 15.0% of patients in the everolimus group (9/60 patients) and 21.1% in the CsA arm (12/57 patients) (*p* = 0.600) \[[@CR16]\].

The incidence of CNI-induced toxicity based on histological analysis was approximately twice as high in the CsA cohort as in those switched to everolimus, but the absolute difference was relatively small (4.5% versus 10.3%). This is perhaps not unexpected since it is accounted for by the fact that the first investigator-initiated biopsy was performed at approximately 20 months post-transplant in both groups. The histological lesions which characterize CNI nephrotoxicity (arteriolar hyalinosis, striped cortical fibrosis, tubular microcalcification) develop progressively over time \[[@CR17]\]. In a study of sequential protocol biopsies, Nankivell et al. showed that approximately 25% of patients had CNI-induced lesions by month 6, doubling to half of all patients by year 5 \[[@CR17]\], but in our series the low rate of protocol biopsies was inadequate to offer meaningful data on subclinical CNI-related nephrotoxicity.

Protocol-specified biopsies were requested but were not mandatory, and were performed in accordance with local center practice. In fact, protocol biopsies were performed in only 13% of patients at randomization and in only 11% at month 12, presumably since this conflicted with local practice. Regrettably, biopsy data from 26 patients did not specify whether they were protocol- or clinically-mandated, and were therefore excluded from the current analysis since they could not reliably be assigned to a category. The resulting small numbers preclude reliable interpretation and negate the possibility for a matched/paired analysis. Previously, the CERTITEM study has reported a higher rate of subclinical rejection in kidney transplant patients switched from CNI therapy to everolimus at month 3 post-transplant versus those who continued CNI (10.4% versus 2.0%, *p* = 0.015) \[[@CR18]\]. In that trial, however, the everolimus-treated population was under-immunosuppressed due to 50% reduction in mycophenolic acid dose. Here, a difference in subclinical rejection appears unlikely since there was no indication of greater long-term histological deterioration under everolimus based on investigator-initiated biopsies and since renal function remained superior to the CNI treatment group to 5 years post-transplant \[[@CR11]\].

The ZEUS trial offered the benefit of a randomized, multicenter study design with long-term follow-up to 5 years, and a balanced proportion of patients in each treatment group providing at least one biopsy sample after randomization. All pathological assessments were carried out locally at the 17 participating centers to ensure rapid information for clinical decision-making, and inevitably this introduces the risk of variability in pathological assessments between centers \[[@CR19], [@CR20]\]. There is no reason to expect, however, that this variability influenced the between-group comparison. Also, more than 60% of investigator-initiated biopsies were undertaken after year 1, offering a good comparison of the effect of the two treatment regimens on graft histology over the first 5 years after kidney transplantation. It is also important to note that by the end of the five-year follow-up period, only 45% of patients in the everolimus arm were still receiving everolimus, and only 59% of those randomized to CsA continued to receive CsA.

Clinical analyses of data from the ZEUS study at one \[[@CR10]\] and five \[[@CR11]\] years post-transplant have shown superior graft function after switch from CsA to everolimus therapy, with a higher rate of mild acute cellular rejection reported by clinicians in the everolimus cohort at year 1. This more detailed analysis of histological findings from the ZEUS study confirms the preponderance of early mild BPAR cases in the CNI-free everolimus-arm as published before \[[@CR10]\], but with no increase in AMR and a lower rate of CNI-related toxicity. These findings suggest that conversion from CsA to everolimus by month 6 after kidney transplantation, with concomitant mycophenolic acid and steroids, can be undertaken safely and offers the possibility to reduce CNI-related toxicity.

Additional file
===============

 {#Sec16}

Additional file 1:**Table S1.** Baseline characteristics (safety population). **Table S2.** Immunosuppression at 5 years post-transplant (safety population), *n* (%). **Table S3.** Pathology assessment of biopsies according to Banff criteria in patients with ≥1 biopsy not categorized as 'protocol-specified' or 'investigator-initiated'. **Figire S1.** CsA, cyclosporine. (DOCX 129 kb)
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